Compare Novavax Inc (NVAX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Prospect Capital Corporation — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Prospect Capital Corporation trades at $2.17 (market cap $1.12B). The key difference: Novavax Inc is the larger of the two by market cap, and Prospect Capital Corporation pays a 22.42% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PSEC | |
|---|---|---|
Market Cap | $1.30B | $1.12B |
Sector | Health | Financials |
52-Week High | $11.19 | $3.47 |
52-Week Low | $6.22 | $2.15 |
Enterprise Value | $800.50M | — |
Dividend Yield | — | 22.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
